Commonly used primary combination regimens in Waldenström macroglobulinemia
| Number of patients . | Regimen . | ORR (%) . | ≥PR/CR (%) . | TTNT (mo)* . | PFS (mo)* . | OS (mo)* . |
|---|---|---|---|---|---|---|
| Proteasome inhibitor–based | ||||||
| 26 | Bortezomib-rituximab | 89 | 66/4 | NR | NR | 96% at 1 y |
| 23 | BDR (WMCTG) | 96 | 91/17 | — | 57% at 5y | Median NR, 95% at 5 y |
| 59 | BDR (EMN) | 85 | 68/3 | 73 | 43 | 66% at 7 y |
| 42 | BCR vs | 98 | 79/2 | — | — | — |
| 17 | FCR (R2W) | 82 | 77/0 | — | — | — |
| 31† | CaRD | 87 | 67/3 | NR | — | |
| 26 | IDR | 88 | 50/0 | — | — | — |
| Non–proteasome inhibitor–based | ||||||
| 169 | Chlorambucil vs | — | 36 | 27 | 70 | |
| 170 | fludarabine (WM1) | 46 | 38 | NR | ||
| 72 | DRC | 83 | 74/7 | 51 | Median 95, 64% at 8 y | |
| 22 | Bendamustine-rituximab vs | 95 | –/– | — | 70 | — |
| 19 | R-CHOP (STiL) | 95 | 28 | |||
| 29† | Cladribine-rituximab | 90 | –/25 | — | — | — |
| 43† | FCR | 79 | 74/12 | — | NR | 69 |
| Number of patients . | Regimen . | ORR (%) . | ≥PR/CR (%) . | TTNT (mo)* . | PFS (mo)* . | OS (mo)* . |
|---|---|---|---|---|---|---|
| Proteasome inhibitor–based | ||||||
| 26 | Bortezomib-rituximab | 89 | 66/4 | NR | NR | 96% at 1 y |
| 23 | BDR (WMCTG) | 96 | 91/17 | — | 57% at 5y | Median NR, 95% at 5 y |
| 59 | BDR (EMN) | 85 | 68/3 | 73 | 43 | 66% at 7 y |
| 42 | BCR vs | 98 | 79/2 | — | — | — |
| 17 | FCR (R2W) | 82 | 77/0 | — | — | — |
| 31† | CaRD | 87 | 67/3 | NR | — | |
| 26 | IDR | 88 | 50/0 | — | — | — |
| Non–proteasome inhibitor–based | ||||||
| 169 | Chlorambucil vs | — | 36 | 27 | 70 | |
| 170 | fludarabine (WM1) | 46 | 38 | NR | ||
| 72 | DRC | 83 | 74/7 | 51 | Median 95, 64% at 8 y | |
| 22 | Bendamustine-rituximab vs | 95 | –/– | — | 70 | — |
| 19 | R-CHOP (STiL) | 95 | 28 | |||
| 29† | Cladribine-rituximab | 90 | –/25 | — | — | — |
| 43† | FCR | 79 | 74/12 | — | NR | 69 |
BCR, bortezomib-cyclophosphamide-rituximab; CaRD, carfilzomib-rituximab-dexamethasone; CR, complete response; FCR, fludarabine-cyclophosphamide-rituximab; IDR, ixazomib-dexamethasone-rituximab; NR, not reached; OS, overall survival; PR, partial response; R-CHOP, rituximab-doxorubicin-cyclophosphamide-vincristine-prednisone; WM1, Waldenström macroglobulinemia 1; WMCTG, Waldenström Macroglobulinemia Clinical Trials Group.
Median (in months), unless otherwise specified.
Heterogeneous cohort, including relapsed and/or refractory patients with WM.